top of page

Search Results

42 results found for "Shivani Sachdev"

Posts (33)

  • 📰 GPCR Weekly News, May 27 to June 2, 2024

    GPCR contributor article Canonical chemokine receptors as scavenging “decoys” Shivani Sachdev, Brendan

  • A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation

    September 2022 "Melanocortin 4 receptor (MC4R) is part of the leptin-melanocortin pathway and plays an essential role in mediating energy homeostasis. Mutations in the MC4R are the most frequent monogenic cause for obesity. Due to increasing numbers of people with excess body weight, the MC4R has become a target of interest in the search of treatment options. We have previously reported that the MC4R forms homodimers, affecting receptor Gs signaling properties. Recent studies introducing setmelanotide, a novel synthetic MC4R agonist, suggest a predominant role of the Gq/11 pathway regarding weight regulation. In this study, we analyzed effects of inhibiting homodimerization on Gq/11 signaling using previously reported MC4R/CB1R chimeras. NanoBRETTM studies to determine protein–protein interaction were conducted, confirming decreased homodimerization capacities of chimeric receptors in HEK293 cells. Gq/11 signaling of chimeric receptors was analyzed using luciferase-based reporter gene (NFAT) assays. Results demonstrate an improvement of alpha-MSH-induced NFAT signaling of chimeras, reaching the level of setmelanotide signaling at wild-type MC4R (MC4R-WT). In summary, our study shows that inhibiting homodimerization has a setmelanotide-like effect on Gq/11 signaling, with chimeric receptors presenting increased potency compared to MC4R-WT. These findings indicate the potential of inhibiting MC4R homodimerization as a therapeutic target to treat obesity." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR

    To achieve this, the work of Heydenreich et al. (2023) will be analysed to demonstrate how mutagenesis This distinction is essential for designing drugs that selectively target these residues to achieve desired patient with a specific variant of the β2AR gene that reduces potency might require a higher drug dose to achieve

View All

Other Pages (9)

  • Ep 116 with Dr. Shivani Sachdev

    Shivani Sachdev Dr. GPCR Podcast << Back to podcast list Dr. Shivani Sachdev About Dr. Shivani Sachdev "Dr. Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid Shivani Sachdev on the web NIDDK ReseachGate Google Scholar LinkedIn Twitter Dr.

  • Ep 150 with Dr GPCR Team

    Shivani Sachdev Dr. Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid Shivani Sachdev on the web NIDDK ReseachGate Google Scholar LinkedIn Twitter Dr. GPCR About Dr.

  • About Yamina | Dr. GPCR Ecosystem

    Briefly describe your specific position, including details about important achievements and milestones Briefly describe your specific position, including details about important achievements and milestones Briefly describe your specific position, including details about important achievements and milestones

View All

Powered by


All Rights Reserved © 2020 - 2024

Dr. GPCR CORP is a 501(c)(3) non profit organization

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page